News Daily News EMA: No Evidence of Link Between GLP-1 Receptor Agonists and Suicidal Thoughts Todd Neale April 12, 2024
News Conference News ACC 2024 Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing Michael O'Riordan April 12, 2024
News Conference News ACC 2024 KARDIA-2: Zilebesiran Drops BP on Top of Common Antihypertensives Shelley Wood April 11, 2024
News Conference News ACC 2024 Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL Yael L. Maxwell April 09, 2024
News Conference News ACC 2024 ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI Yael L. Maxwell April 07, 2024
News Conference News ACC 2024 Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI Michael O'Riordan April 07, 2024
News Conference News ACC 2024 Full AEGIS-II Results: Raising HDL With Apo A-I No Help After Acute MI Yael L. Maxwell April 06, 2024
News Conference News ACC 2024 Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI Shelley Wood April 06, 2024
News Daily News Class I Recall for 330,000 Radial Artery Catheterization Kits: FDA Yael L. Maxwell April 03, 2024
News Industry News Concept Medical receives US FDA approval for MagicTouch AVF indication, their fifth US clinical study approval for the MagicTouch portfolio April 03, 2024
News Conference News ACC 2024 ADHD Meds Linked to Cardiomyopathy in Young Adults Todd Neale April 01, 2024
News Features The Promise of Pulsed-Field Ablation: Cautious Optimism Amid Some Unknowns Todd Neale March 29, 2024
News Opinion Off Script Evoque and Patisiran: A Tale of Two Regulatory Journeys Sanjay Kaul, MD March 29, 2024
News Daily News When Moving From DAPT to Monotherapy After PCI, the P2Y12 Inhibitor Matters Yael L. Maxwell March 21, 2024
News Daily News Patients With CKD Remain Underrepresented in Trials of CV Meds Todd Neale March 08, 2024
News Daily News AHA Sums Up AI’s Potential in Cardiology, but Also the Hurdles Ahead Yael L. Maxwell March 07, 2024
News Conference News THT 2024 Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients Michael O'Riordan March 07, 2024